EPIDAREX CAPITAL – CATALYZING INNOVATION IN HEALTH SCIENCE AND TECHNOLOGY
Newhouse, United Kingdom, October 26, 2016 – Clyde Biosciences today announced the launch of a new service to serve the needs of its global pharma
Brighton, UK, October 17, 2016 – Enterprise Therapeutics Ltd, a drug discovery company dedicated to the research and development of novel therapies for the treatment
Edinburgh, Scotland, October 7, 2016 – At the OBN Awards 2016 dinner in Oxford last night, Edinburgh Molecular Imaging were awarded the Best Emerging Medtech Company
LOUISVILLE, Ky., Aug. 8, 2016 – Apellis Pharmaceuticals, Inc., a clinical stage complement immunotherapy company, announced today the expansion of its executive team with the addition of Dr.
Business Quarter interviews Sinclair Dunlop, Managing Partner of Epidarex Capital on venture capital, innovation, and the funding gap in Scotland. Click here for a link
LOUISVILLE, Ky., June 23, 2016 – Apellis Pharmaceuticals, Inc. today announced positive results from two Phase 1 clinical trials of its complement C3 inhibitor, APL-2.
Glasgow, Scotland, UK, 20th June 2016: Mironid Ltd, a leader in cell signalling directed drug development, today announced the closing of its Series A funding